BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 12577243)

  • 1. Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): a new concept in radiotherapy and encouraging results in breast cancer.
    Koukourakis MI
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):42-6. PubMed ID: 12577243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
    Koukourakis MI; Yannakakis D
    Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypofractionated and accelerated radiotherapy with subcutaneous amifostine cytoprotection as short adjuvant regimen after breast-conserving surgery: interim report.
    Koukourakis MI; Tsoutsou PG; Abatzoglou IM; Sismanidou K; Giatromanolaki A; Sivridis E
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1173-80. PubMed ID: 19058920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of low-risk prostate cancer with radical hypofractionated accelerated radiotherapy with cytoprotection (HypoARC): an interim analysis of toxicity and efficacy.
    Koukourakis MI; Kyrgias G; Papadopoulou A; Panteliadou M; Giatromanolaki A; Sivridis E; Mavropoulou S; Kalogeris K; Nassos P; Milioudis N; Touloupidis S
    Anticancer Res; 2011 May; 31(5):1745-51. PubMed ID: 21617234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer.
    Koukourakis MI; Papadopoulou A; Abatzoglou I; Panteliadou M; Sismanidou K; Touloupidis S
    Anticancer Res; 2012 Oct; 32(10):4561-8. PubMed ID: 23060587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformal hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC) for high risk prostatic carcinoma: rationale, technique and early experience.
    Koukourakis MI; Touloupidis S; Manavis J; Abatzoglou I; Sismanidou K; Sivridis L
    Anticancer Res; 2004; 24(5B):3239-43. PubMed ID: 15510617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computed tomography (CT) scan evaluation of late toxicity following hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) in breast cancer patients treated with conservative surgery.
    Manavis J; Ambatzoglou J; Sismanidou K; Koukourakis MI
    Am J Clin Oncol; 2006 Oct; 29(5):479-83. PubMed ID: 17023783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
    Koukourakis MI; Giatromanolaki A; Kouroussis C; Kakolyris S; Sivridis E; Frangiadaki C; Retalis G; Georgoulias V;
    Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):144-55. PubMed ID: 11777632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postmastectomy hypofractionated and accelerated radiation therapy with (and without) subcutaneous amifostine cytoprotection.
    Koukourakis MI; Panteliadou M; Abatzoglou IM; Sismanidou K; Sivridis E; Giatromanolaki A
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e7-13. PubMed ID: 23040218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
    Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI
    Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypofractionated accelerated radiochemotherapy with cytoprotection (Chemo-HypoARC) for inoperable non-small cell lung carcinoma.
    Koukourakis MI; Patlakas G; Froudarakis ME; Kyrgias G; Skarlatos J; Abatzoglou I; Bougioukas G; Bouros D
    Anticancer Res; 2007; 27(5B):3625-31. PubMed ID: 17972527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer.
    Koukourakis MI; Tsolos C; Touloupidis S
    Urology; 2007 Feb; 69(2):245-50. PubMed ID: 17320657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated accelerated radiotherapy, cytoprotection and capecitabine in the treatment of rectal cancer: a feasibility study.
    Koukourakis MI; Simopoulos C; Pitiakoudis M; Lyratzopoulos N; Romanidis K; Giatromanolaki A; Polychronidis A; Kouklakis G; Sivridis E; Minopoulos G; Manolas K
    Anticancer Res; 2008; 28(5B):3035-40. PubMed ID: 19031952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualization of the subcutaneous amifostine dose during hypofractionated / accelerated radiotherapy.
    Koukourakis MI; Abatzoglou I; Sivridis L; Tsarkatsi M; Delidou H
    Anticancer Res; 2006; 26(3B):2437-43. PubMed ID: 16821629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential for use of amifostine in cervical cancer.
    Small W
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):34-7. PubMed ID: 12577241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose escalation of amifostine for radioprotection during pelvic accelerated radiotherapy.
    Koukourakis MI; Kyrgias G; Panteliadou M; Papadopoulou A; Tsiarkatsi M; Papachristou E; Bebeli M
    Am J Clin Oncol; 2013 Aug; 36(4):338-43. PubMed ID: 22643562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of invasive bladder cancer with conformal hypofractionated accelerated radiotherapy and amifostine (HypoARC).
    Panteliadou M; Giatromanolaki A; Touloupidis S; Destouni E; Tsoutsou PG; Pantelis P; Abatzoglou I; Sismanidou K; Koukourakis MI
    Urol Oncol; 2012; 30(6):813-20. PubMed ID: 21163674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
    Anné PR
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
    Bourhis J; Rosine D
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
    Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
    Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.